The global lactated ringers injection market is estimated to be valued at USD 510.1 Mn in 2024 and is expected to reach USD 762.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031. Lactated ringers injection is one of the most commonly prescribed intravenous fluids used for fluid resuscitation and management of dehydration. It helps restore electrolyte balance and fluid volume in the body. The global lactated ringers injection market has been witnessing steady growth in the recent past due to the rising prevalence of chronic diseases and injuries that require intravenous therapy. Furthermore, the growing geriatric population who are more prone to electrolyte imbalance is also contributing to the increased demand for lactated ringers injection. With growing awareness and improved access to healthcare facilities globally, the market is expected to continue its positive outlook over the forecast period.
Market Dynamics:
The global lactated ringers injection market has been experiencing steady growth attributed to the rising prevalence of chronic health conditions such as diabetes, cardiovascular diseases, and kidney ailments that often lead to electrolyte imbalance. Additionally, the growing risk of road accidents, injuries, and trauma cases requiring emergency fluid resuscitation are further propelling market growth. Furthermore, the growing geriatric population who are more susceptible to electrolyte disorders is creating high maintenance demand for lactated ringers injection. However, stringent regulations pertaining to intravenous fluid approvals may hinder market growth. Moreover, the availability of alternative IV therapy products acts as a restraint. On the other hand, increasing healthcare investments in emerging nations provide significant opportunities for market players.
Key Features of the Study:
- This report provides in-depth analysis of the global lactated ringers injection market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global lactated ringers injection market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Baxter International Inc., B. Braun Melsungen AG, ICU Medical, Inc., Fresenius Kabi AG, Hospira, Inc., Otsuka Pharmaceutical Co., Ltd., Dechra Pharmaceuticals PLC, Vedco, Inc., Grifols S.A., Pfizer Inc., Amgen Inc., Eton Pharmaceuticals, Inc., Sagent Pharmaceuticals, Inc., and Aurobindo Pharma Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global lactated ringers injection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lactated ringers injection market
Market Segmentation
Market Segmentation
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients